---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247525553.md"
description: "Prime Medicine Inc. (PRME) maintained an increase of over 32.4%, once achieving the best intraday performance since September 2024, with a cumulative increase of approximately 67.3% over the last five trading days, attracting investor interest with its gene editing technology"
datetime: "2025-07-07T16:10:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247525553.md)
  - [en](https://longbridge.com/en/news/247525553.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247525553.md)
generator: "portal-rs"
---

# 

Prime Medicine Inc. (PRME) maintained a gain of over 32.4%, once achieving its best intraday performance since September 2024, with a cumulative increase of approximately 67.3% over the last five trading days, attracting investor interest with its gene editing technology

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)

## Related News & Research

- [Innometry to attend Kiwoom Securities-hosted corporate day investor briefing](https://longbridge.com/en/news/301521983.md)
- [The legendary Citroen 2CV is back as a €15k electric concept for 2028](https://longbridge.com/en/news/301515456.md)
- [LG Chem subsidiary FarmHannong debuts E-COAT eco-friendly fertilizer brand at Japan J-AGRI show](https://longbridge.com/en/news/301522374.md)
- [Nuclearelectrica keeps Cernavodă nuclear units 1 and 2 in safe shutdown amid low Danube water levels](https://longbridge.com/en/news/301501802.md)
- [China agrees to limit hybrid exports to the EU](https://longbridge.com/en/news/301500641.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**